Concepedia

Katherine Garlo

KG

Statistics

Publications

14

Citations

832

H-Index

12

Active since

2010

Affiliations

Alexion Pharmaceuticals (United States)(Current)

AstraZeneca (United States)

Brigham and Women's Hospital

Emory University

Harvard University

Katherine Garlo is an author at Alexion Pharmaceuticals (United States) specializing in medicine, pharmacotherapy, and ravulizumab therapy.

Publications per year

2010–2024

14

Publications

14

Burden in Caregivers of Older Adults with Advanced Illness

Katherine Garlo, John R. O’Leary, Peter H. Van Ness et al. · Journal of the American Geriatrics Society · 2010 · 315 citations · Full text

, , +16

Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation

Thomas A. Mavrakanas, Katherine Garlo, David M. Charytan · Clinical Journal of the American Society of Nephrology · 2020 · 96 citations · Full text

, , +14

Chronotype is associated with the timing of the circadian clock and sleep in toddlers

Charles T. Simpkin, Oskar G. Jenni, Mary A. Carskadon et al. · Journal of Sleep Research · 2014 · 92 citations · Full text

, , +15

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Thomas Barbour, Marie Scully, Gema Ariceta et al. · Kidney International Reports · 2021 · 66 citations · Full text

, , +17

Efficacy and Safety of Ravulizumab in IgA Nephropathy

Richard Lafayette, James Tumlin, Roberta Fenoglio et al. · Journal of the American Society of Nephrology · 2024 · 58 citations · Full text

, , +17

1–5 of 14